tiprankstipranks
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP

NRX Pharmaceuticals (NRXP) Income Statement

285 Followers

NRX Pharmaceuticals Income Statement

Last quarter (Q4 2023), NRX Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, NRX Pharmaceuticals's net income was $-6.53M. See NRX Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
----$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 28.03M$ 27.84M$ 44.34M$ -115.80M$ 11.90M
Operating Income
$ -28.03M$ -27.84M$ -44.34M$ -115.80M$ -11.90M
Net Non Operating Interest Income Expense
$ -1.68M$ 374.00K$ 249.00K$ 20.92M$ -56.00K
Other Income Expense
$ -537.00K$ -2.69M$ 3.82M$ -121.00K$ -39.82M
Pretax Income
$ -29.16M$ -30.15M$ -39.75M$ -93.06M$ -51.78M
Tax Provision
$ -4.28M$ -4.28M$ -9.29M$ -11.76M$ 0.00
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -29.30M$ -30.16M$ -39.75M$ -350.55M$ -51.78M
Basic EPS
$ -1.07$ -0.40$ -1.20$ -1.98$ -1.51
Diluted EPS
$ -1.07$ -0.40$ -1.20$ -1.98$ -1.51
Basic Average Shares
$ 229.95M$ 75.76M$ 65.77M$ 46.92M$ 34.27M
Diluted Average Shares
$ 229.95M$ 75.76M$ 65.77M$ 46.92M$ 34.27M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 28.03M$ 27.84M$ 44.34M$ -115.80M$ 11.90M
Net Income From Continuing And Discontinued Operation
$ -30.62M$ -30.15M$ -39.75M$ -94.75M$ -51.78M
Normalized Income
$ -20.51M$ -28.76M--$ -51.44M
Interest Expense
----$ 56.00K
EBIT
$ -28.84M$ -30.03M$ -39.75M$ -93.05M$ -51.72M
EBITDA
$ -28.83M$ -30.02M$ -39.75M$ -93.04M$ -51.72M
Currency in USD

NRX Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis